Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Change in Cash (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Change in Cash for 12 consecutive years, with -$24.0 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Cash fell 94.77% year-over-year to -$24.0 million; the TTM value through Mar 2026 reached $173.9 million, up 670.8%, while the annual FY2025 figure was $178.5 million, 674.57% up from the prior year.
  • Change in Cash hit -$24.0 million in Q1 2026 for Crescent Biopharma, down from $79.9 million in the prior quarter.
  • Across five years, Change in Cash topped out at $130.3 million in Q2 2025 and bottomed at -$24.0 million in Q1 2026.
  • Average Change in Cash over 5 years is $8.8 million, with a median of -$8.6 million recorded in 2022.
  • Year-over-year, Change in Cash plummeted 201.0% in 2022 and then skyrocketed 224.7% in 2023.
  • Crescent Biopharma's Change in Cash stood at -$3.8 million in 2022, then crashed by 102.84% to -$7.6 million in 2023, then tumbled by 38.04% to -$10.5 million in 2024, then surged by 860.39% to $79.9 million in 2025, then plummeted by 130.06% to -$24.0 million in 2026.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$24.0 million, $79.9 million, and $130.3 million for Q1 2026, Q4 2025, and Q2 2025 respectively.